Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant Staphylococcus aureus

Abstract

Twice-daily 7-day regimens of tigecycline (7 mg/kg) and vancomycin (50 mg/kg) were compared in a rat tissue cage model of chronic foreign-body infection due to methicillin (meticillin)-resistant Staphylococcus aureus strain MRGR3. Subcutaneously administered tigecycline reached levels in tissue cage fluid that were nearly equivalent or slightly superior to the antibiotic MIC (0.5 g/ml) for strain MRGR3. After 7 days, equivalent, significant reductions in bacterial counts were recorded for tigecycline-treated and vancomycin-treated rats, compared with those for untreated animals.

Clonality, virulence and the occurrence of genes encoding antibiotic resistance among Staphylococcus warneri isolates from bloodstream infections

“…However, rifampicin monotherapy quickly results in rifampicin resistance and, for this reason, at least one further active antimicrobial agent was required to be used with rifampicin (Yin et al, 2005). Tigecycline, a novel, glycylcycline antibiotic, has demonstrated a good activity in various animal models against foreign-body infections due to meticillin-resistant Staphylococcus aureus (MRSA) (Murphy et al, 2000;Vaudaux et al, 2009). It is important to point out that no antagonism was observed between tigecycline and rifampicin (Petersen et al, 2006).…”

Spontaneous Knee Hemarthrosis Due to Hypofibrinogenemia Following Tigecycline Treatment for Periprosthetic Joint Infection

“…In a recent in vitro study, tigecycline, along with rifampicin, showed superior activity against a Staphylococcus epidermidis biofilm in comparison with ciprofloxacin, vancomycin, cloxacillin, and daptomycin [7]. Additionally, animal studies show that tigecycline is active against foreign body infections, as monotherapy or in combination with other antimicrobial agents [8][9]. Although there is limited experience in the treatment of periprosthetic joint infection because of the biofilm and the MDRO, the use of high dosage tigecycline administration was chosen to maximize the effectiveness of the drug [6,10].…”

Clinical Experience with Tigecycline in the Treatment of Prosthetic Joint Infections

“…In vitro and animal studies suggest that tigecycline may be useful in the setting of PJI. Vaudaux et al demonstrated that tigecycline is equally effective compared to vancomycin in treatment of MRSA foreign body infection in the rat model 15, while Corvec et al suggested that tigecycline functions better when given in combination with colistin or fosfomycin against extended-spectrum-β-lactamase-producing Escherichia coli in a tissue cage model of infection 16. Molina-Manso et al examined in vitro susceptibility of staphylococci to antimicrobials in orthopedic biofilm infections 7.…”